Project title: Biomarkers of response to cabozantinib in patients with neuroendocrine tumors
Jennifer Chan, MD, MPH Dana-Farber Cancer Center
- Status: Completed
- Year(s): 2018
- Grant Type: Pilot
- Research Type: Clinical
- Primary Tumor Site: Pancreas/small intestine
- Area of Inquiry: Clinical trials
- Article/Video: Click Here
- Also seen in September 2018 eUpdate
General Description
This one-year Pilot Project will evaluate data and patient samples from a phase II clinical trial of cabozantinib, a targeted therapy that showed promise in treating NETs. Cabozantinib has been shown to induce cancer cell death in other types of cancers. In this study, Chan and colleagues will analyze samples from their clinical trial to look for biomarkers that could predict response to cabozantinib. Their findings will be applied to a future investigation in a phase III clinical trial of cabozantinib in NET planned by Chan and colleagues.Additional Details
- City: Boston
- State: Massachusetts
- Grant Duration: 1 year
- Awards: Pilot Project
DISCLAIMER
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.